Concurrent Intra-Arterial Chemotherapy and Radiotherapy for Advanced Laryngeal Cancer

Ann Otol Rhinol Laryngol. 2009 Mar;118(3):172-8. doi: 10.1177/000348940911800303.

Abstract

Objectives: An intra-arterial chemoradiotherapy regimen (RADPLAT) provides remarkable local control for head and neck cancer. This study evaluates the efficacy of a reduced RADPLAT protocol in patients who are candidates for total laryngectomy.

Methods: Forty-three patients with advanced laryngeal cancer were treated with 2 courses of intra-arterial cisplatin infusion (100 mg per body) during 40-Gy irradiation. The patients who showed a greatly diminished tumor received sequential irradiation. The patients with obvious residual disease received chemotherapy during the sequential irradiation. Poor responders, with less than 50% tumor reduction, underwent total laryngectomy.

Results: Forty-two patients completed the protocol. All surviving patients were followed for at least 3 years. Thirty-four patients were alive (80% of the supraglottic cases and 87.5% of the glottic cases). Local control was achieved in 27 patients (67.5% of the 11 glottic cases and 64.0% of the supraglottic cases). The glottic cohort showed better progression-free survival rates than did the supraglottic cohort (68.8% and 45.0%, respectively; p = 0.019). There were 2 cases of grade 3 neutropenia and 3 cases of grade 3 mucositis. No patients required tube feeding. One patient required tracheostomy 3 months after the completion of the treatment protocol.

Conclusions: Concurrent chemoradiotherapy with a reduced dose of intra-arterial cisplatin is feasible for patients with advanced glottic cancer.

Publication types

  • Clinical Trial

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Carcinoma, Squamous Cell / mortality
  • Carcinoma, Squamous Cell / pathology
  • Carcinoma, Squamous Cell / therapy*
  • Cisplatin / administration & dosage*
  • Cohort Studies
  • Disease-Free Survival
  • Dose Fractionation, Radiation
  • Female
  • Humans
  • Infusions, Intra-Arterial
  • Laryngeal Neoplasms / mortality
  • Laryngeal Neoplasms / pathology
  • Laryngeal Neoplasms / therapy*
  • Male
  • Middle Aged
  • Radiotherapy, Adjuvant
  • Survival Rate
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Cisplatin